Zivo Bioscience Corrects Director Fee Stock Award Date

TL;DR

Zivo Bioscience fixed a typo on a director stock award date from 2023.

AI Summary

Zivo Bioscience, Inc. filed an amendment (8-K/A) on June 7, 2024, to correct a typographical error in a previous Form 8-K dated May 31, 2024. The correction pertains to the date cited for a stock award granted in lieu of unpaid directors' fees, which is now correctly stated as 'December 29, 2023'. This amendment specifically addresses Item 1.01 of the original filing.

Why It Matters

This filing clarifies a specific date related to director compensation, ensuring accuracy in the company's public disclosures regarding stock awards.

Risk Assessment

Risk Level: low — This is a minor administrative amendment to correct a typographical error in a previous filing, with no new material information or changes to the company's business operations.

Key Players & Entities

• Zivo Bioscience, Inc. (company) — Filer of the 8-K/A
• May 31, 2024 (date) — Date of the Original Form 8-K
• June 7, 2024 (date) — Filing date of the 8-K/A
• December 29, 2023 (date) — Corrected date for stock award in lieu of unpaid directors' fees
• Item 1.01 (document_section) — Section of the filing being amended

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ZIVO OTCQB Warrants to p
• $172,670 — ed the three non-employee board members $172,670 in fees; Alison Cornell was due $62,789
• $62,789 — 172,670 in fees; Alison Cornell was due $62,789, Nola Masterson was due $56,062, and Ch
• $56,062 — was due $62,789, Nola Masterson was due $56,062, and Chris Maggiore was due $53,819. Th
• $53,819 — due $56,062, and Chris Maggiore was due $53,819. These unpaid amounts were grossed up f
• $1.20 — ing stock price on December 29, 2023 of $1.20 per share. On June 5, 2024, all the non

Filing Documents

• zivo_8ka.htm (8-K/A) — 29KB
• 0001654954-24-007479.txt ( ) — 152KB
• zivo-20240606.xsd (EX-101.SCH) — 6KB
• zivo-20240606_lab.xml (EX-101.LAB) — 14KB
• zivo-20240606_cal.xml (EX-101.CAL) — 1KB
• zivo-20240606_pre.xml (EX-101.PRE) — 9KB
• zivo-20240606_def.xml (EX-101.DEF) — 2KB
• zivo_8ka_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement Stock Award in Lieu of Unpaid Directors' Fees On May 31, 2024 the Board approved a Stock in Lieu of Unpaid Director's program fees that would allow for the granting of a total of 261,619 shares of stock to the non-employee Board members common in lieu of unpaid non-employee director service fees earned during the calendar year ending December 31, 2023. In aggregate the Company owed the three non-employee board members $172,670 in fees; Alison Cornell was due $62,789, Nola Masterson was due $56,062, and Chris Maggiore was due $53,819. These unpaid amounts were grossed up for taxes at an assumed tax rate of 45% and the number of shares was determined based on the Company's closing stock price on December 29, 2023 of $1.20 per share. On June 5, 2024, all the non-employee directors accepted the following grants in lieu of the unpaid cash service fees: Non-employee Board Member Shares Awarded Alison Cornell 95,134 Chris Maggiore 81,544 Nola Masterson 84,941 The value of the shares granted to the non-employee directors pursuant to this exchange of stock in lieu of unpaid cash fees were exempted from the annual limitation of awards to non-employee directors set forth in the Director Equity Plan. These shares awards will be issued under the Director Equity Plan and will be subject to provisions thereof. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZIVO BIOSCIENCE, INC. By: /s/ Keith Marchiando Keith Marchiando Chief Financial Officer Date: June 7, 2024 3

View Full Filing

View this 8-K/A filing on SEC EDGAR